Teradyne, Inc. reported its third quarter 2026 financial results, posting revenue of $1,306 million and GAAP net income attributable to Teradyne of $342.4 million, or $2.17 per diluted share. Results exceeded the high end of previous guidance driven by AI-related demand across memory and integrated systems test. For the fourth quarter of 2026, the company expects revenue between $1,250 million and $1,350 million.
Q3 2026 revenue reached $1,306 million, compared to $769 million in Q3 2025.
GAAP diluted EPS was $2.17 for the quarter ended September 27, 2026, up from $0.75 a year earlier.
Q4 2026 revenue guidance is set between $1,250 million and $1,350 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Teradyne's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$3.19B
+13.1%
$3.47
+4.5%
17.4%
FY2024
$2.82B
+5.4%
$3.32
+21.6%
19.2%
FY2023
$2.68B
-15.2%
$2.73
-35.3%
16.8%
FY2022
$3.16B
-14.8%
$4.22
-23.7%
22.7%
FY2021
$3.70B
+18.6%
$5.53
+29.2%
27.4%
Frequently asked questions
When is Teradyne's next earnings date?
Teradyne has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Teradyne earn last quarter?
For the quarter ended Sep 2026, Teradyne reported diluted EPS of $2.17 (+189.3% year over year) on revenue of $1.31B (+69.8%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.